260 related articles for article (PubMed ID: 30489502)
1. Influence of Treating Ocular Surface Disease on Intraocular Pressure in Glaucoma Patients Intolerant to Their Topical Treatments: A Report of 10 Cases.
Dubrulle P; Labbé A; Brasnu E; Liang H; Hamard P; Meziani L; Baudouin C
J Glaucoma; 2018 Dec; 27(12):1105-1111. PubMed ID: 30489502
[TBL] [Abstract][Full Text] [Related]
2. Ocular surface disease exacerbated glaucoma: optimizing the ocular surface improves intraocular pressure control.
Batra R; Tailor R; Mohamed S
J Glaucoma; 2014 Jan; 23(1):56-60. PubMed ID: 22828007
[TBL] [Abstract][Full Text] [Related]
3. Relation between office intraocular pressure and 24-hour intraocular pressure in patients with primary open-angle glaucoma treated with a combination of topical antiglaucoma eye drops.
Nakakura S; Nomura Y; Ataka S; Shiraki K
J Glaucoma; 2007 Mar; 16(2):201-4. PubMed ID: 17473730
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications.
Fechtner RD; Godfrey DG; Budenz D; Stewart JA; Stewart WC; Jasek MC
Cornea; 2010 Jun; 29(6):618-21. PubMed ID: 20386433
[TBL] [Abstract][Full Text] [Related]
5. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease.
Goldberg I; Graham SL; Crowston JG; d'Mellow G;
Clin Exp Ophthalmol; 2015 Apr; 43(3):214-20. PubMed ID: 25196488
[TBL] [Abstract][Full Text] [Related]
6. Ocular Surface Disease in Patients under Topical Treatment for Glaucoma.
Pérez-Bartolomé F; Martínez-de-la-Casa JM; Arriola-Villalobos P; Fernández-Pérez C; Polo V; García-Feijoó J
Eur J Ophthalmol; 2017 Nov; 27(6):694-704. PubMed ID: 28497458
[TBL] [Abstract][Full Text] [Related]
7. Topical glaucoma therapy and ocular surface disease: a prospective, controlled cohort study.
Saade CE; Lari HB; Berezina TL; Fechtner RD; Khouri AS
Can J Ophthalmol; 2015 Apr; 50(2):132-6. PubMed ID: 25863853
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications.
Lazreg S; Merad Z; Nouri MT; Garout R; Derdour A; Ghroud N; Kherroubi R; Meziane M; Belkacem S; Ouhadj O; Baudouin C; Tiar M
J Fr Ophtalmol; 2018 Dec; 41(10):945-954. PubMed ID: 30477719
[TBL] [Abstract][Full Text] [Related]
9. Intraocular pressure changes following topical ocular hypotensive medications washout.
Ho H; Daas A; Ho J; Alaghband P; Galvis EA; de Antonio Ramirez A; Grassi P; Lim R; Lim KS
Br J Ophthalmol; 2021 Feb; 105(2):205-209. PubMed ID: 32277009
[TBL] [Abstract][Full Text] [Related]
10. Long term effect of phacoemulsification on intraocular pressure in patients with medically controlled primary open-angle glaucoma.
Majstruk L; Leray B; Bouillot A; Michée S; Sultan G; Baudouin C; Labbé A
BMC Ophthalmol; 2019 Jul; 19(1):149. PubMed ID: 31300022
[TBL] [Abstract][Full Text] [Related]
11. Validity of the Monocular Trial of Intraocular Pressure-Lowering at Different Time Points in Patients Starting Topical Glaucoma Medication.
King AJ; Rotchford AP
JAMA Ophthalmol; 2016 Jul; 134(7):742-7. PubMed ID: 27148831
[TBL] [Abstract][Full Text] [Related]
12. Effects of topical low-dose preservative-free hydrocortisone on intraocular pressure in patients affected by ocular surface disease with and without glaucoma.
Filippelli M; dell'Omo R; Gelso A; Rinaldi M; Bartollino S; Napolitano P; Russo A; Campagna G; Costagliola C
Graefes Arch Clin Exp Ophthalmol; 2022 Jan; 260(1):247-253. PubMed ID: 34406502
[TBL] [Abstract][Full Text] [Related]
13. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
[TBL] [Abstract][Full Text] [Related]
14. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
Lopes JF; Hubatsch DA; Amaris P
BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363
[TBL] [Abstract][Full Text] [Related]
15. Long-term relationship between intraocular pressure and visual field loss in primary open-angle glaucoma.
Inatani M; Iwao K; Inoue T; Awai M; Muto T; Koga T; Ogata-Iwao M; Hara R; Futa R; Tanihara H
J Glaucoma; 2008; 17(4):275-9. PubMed ID: 18552612
[TBL] [Abstract][Full Text] [Related]
16. Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives.
Ramli N; Supramaniam G; Samsudin A; Juana A; Zahari M; Choo MM
Optom Vis Sci; 2015 Sep; 92(9):e222-6. PubMed ID: 25730335
[TBL] [Abstract][Full Text] [Related]
17. Twenty-four-hour efficacy of preservative-free tafluprost for open-angle glaucoma patients, assessed by home intraocular pressure (Icare-ONE) and blood-pressure monitoring.
Cho SY; Kim YY; Yoo C; Lee TE
Jpn J Ophthalmol; 2016 Jan; 60(1):27-34. PubMed ID: 26411460
[TBL] [Abstract][Full Text] [Related]
18. [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)].
Ge J; Li X; Sun X; He X; Zhang H
Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):95-102. PubMed ID: 25907999
[TBL] [Abstract][Full Text] [Related]
19. Ocular surface disease incidence in patients with open-angle glaucoma.
Radenković M; Stanković-Babić G; Jovanović P; Djordjević-Jocić J; Trenkić-Božinović M
Srp Arh Celok Lek; 2016; 144(7-8):376-83. PubMed ID: 29652117
[TBL] [Abstract][Full Text] [Related]
20. Selective Laser Trabeculoplasty in Primary Angle-closure Glaucoma After Laser Peripheral Iridotomy: A Case-Control Study.
Ali Aljasim L; Owaidhah O; Edward DP
J Glaucoma; 2016 Mar; 25(3):e253-8. PubMed ID: 26945310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
